Light Science Technologies, the technology and manufacturing business targeting issues including global food security and fire safety, has seen a dip in revenues and widened losses in its latest annual results as it moves through a “transitional period.”
According to audited results for the year ended 30 November 2025, revenue at the firm stood at £8.6m, down from £12m in the year prior, which Light Science said reflected the deliberate reshaping of its portfolio and an anticipated reduction in lower-margin Contract Electronics Manufacturing (CEM) activity.
Meanwhile, the company posted a loss before tax of £0.89m, widening from a £0.03m loss last year, which Light Science shared was driven by timing effects in passive fire protection (PFP) contract conversion and the expected reduction in CEM’s servicing of the pest control market.
Following the year end, the group has announced a successful £6.6m fundraising and the acquisitions of RLUK Injection Ltd (incorporating Injectaclad) and the remaining 10% minority interest in the CEM division’s UK Circuits and Electronics Solutions Limited, together with the associated property.
The enlarged group is positioned to capture a greater share of value chain, says Light Science, and for accelerated growth, targeting higher margin larger contracts and increasing recurring revenues.
Simon Deacon, CEO of LSTH, said: “This was a transitional period for the Group with a focus on creating a platform for high-margin growth across all of our divisions. We rebalanced the sales mix, with PFP and AGT providing the most significant scope for growth, while we further de-risked the CEM division, which is now well positioned to enter Defence, Medical and Healthcare markets.
“The post period end acquisitions will be transformational for the Group, significantly enhancing our profile and ability to generate scale and further grow margins as we target mid-term revenues of c.£50m. We believe that our solutions will become ever more prominent as both legislation – with the recently published BSR Strategic Plan highlighting the need to expedite schemes – and global issues set to underpin increased demand.
“Having successfully completed the £6.6 million fund raise and acquisitions we are well placed for a strong second half of the current financial year as we fully integrate Injectaclad into the Group, which will support growth for the years to come.
“I’d like to thank the current and new investors for their support in the next exciting phase of our development.”